

## 2016 Gastroenterology Preferred Specialty Measure Set

PQRS#	NQF#	Reporting Method	National Quality Strategy Domain	Measure Title: Description
113	0034	Registry, Claims, EHR, GPRO (Web Interface), Measures Groups	Effective Clinical Care	<b>Colorectal Cancer Screening:</b> Percentage of patients 50 through 75 years of age who had appropriate screening for colorectal cancer
185	0659	Claims, Registry	Communication and Care Coordination	<b>Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use:</b> Percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior adenomatous polyp(s) in previous colonoscopy findings, who had an interval of 3 or more years since their last colonoscopy
226	0028	Claims, Registry, EHR, GPRO (Web Interface), Measures Groups	Community/ Population Health	<b>Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention:</b> Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user
320	0658	Claims, Registry	Communication and Care Coordination	<b>Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients: Percentage of patients aged 50 to 75 years of age receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report</b>
343	N/A	Registry	Effective Clinical Care	<b>Screening Colonoscopy Adenoma Detection Rate:</b> The percentage of patients age 50 years or older with at least one conventional adenoma or colorectal cancer detected during screening colonoscopy
387	N/A	Registry	Effective Clinical Care	<b>Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users:</b> Percentage of patients regardless of age who are active injection drug users who received screening for HCV infection within the 12 month reporting period
390	N/A	Registry, Measures Groups	Person and Caregiver-Centered Experience and Outcomes	<b>Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options:</b> Percentage of patients aged 18 years and older with a diagnosis of hepatitis C with whom a physician or other qualified healthcare professional reviewed the range of treatment options appropriate to their genotype and demonstrated a shared decision making approach with the patient. To meet the measure, there must be documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: <ul style="list-style-type: none"> <li>•Treatment choices appropriate to genotype</li> <li>•Risks and benefits</li> <li>•Evidence of effectiveness</li> <li>•Patient preferences toward the outcome of the treatment</li> </ul>
400	N/A	Registry	Effective Clinical Care	<b>One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk:</b> Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis OR birthdate in the years 1945-1965 who received a one-time screening for HCV infection

## 2016 Gastroenterology Preferred Specialty Measure Set

PQRS#	NQF#	Reporting Method	National Quality Strategy Domain	Measure Title: Description
401	N/A	Registry, Measures Groups	Effective Clinical Care	<b>Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in patients with Hepatitis C Cirrhosis:</b> Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who were screened with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period
438	N/A	Claims, Registry	Effective Clinical Care	<b>Statin Therapy for the Prevention and Treatment of Cardiovascular Disease:</b> Percentage of high-risk adult patients aged $\geq 21$ years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR adult patients aged $\geq 21$ years with a fasting or direct Low-Density Lipoprotein Cholesterol (LDL-C) level $\geq 190$ mg/dL; OR patients aged 40-75 years with a diagnosis of diabetes with a fasting or direct Low-Density Lipoprotein Cholesterol (LDL-C) level of 70-189 mg/dL; who were prescribed or are already on statin medication therapy during the measurement period
439	N/A	Registry	Efficiency and Cost Reduction	<b>Age Appropriate Screening Colonoscopy;</b> <b>The percentage of patients greater than 85 years of age who received a screening colonoscopy from January 1 to December 31</b>

This table is a resource of potential measures that may be applicable to eligible professionals providing clinical services for Gastroenterology. Please note that in addition to this table, a cross cutting measures list is also available for reporting at the following link: [2016 Cross-Cutting Measures List](#)